MAVENCLAD Drug Patent Profile

Which patents cover Mavenclad, and when can generic versions of Mavenclad launch?

Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in fourteen countries.

The generic ingredient in MAVENCLAD is cladribine. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the cladribine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mavenclad

A generic version of MAVENCLAD was approved as cladribine by HIKMA on February 28^th, 2000.

Summary for MAVENCLAD

International Patents:	32
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAVENCLAD

Paragraph IV (Patent) Challenges for MAVENCLAD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAVENCLAD	Tablets	cladribine	10 mg	022561	1	2022-04-07

US Patents and Regulatory Information for MAVENCLAD

MAVENCLAD is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,533,408
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	10,849,919
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,539,329

International Patents for MAVENCLAD

See the table below for patents covering MAVENCLAD around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	3332789
South Korea	101129816
Portugal	1608344
Eurasian Patent Organization	200600404	ПЕРОРАЛЬНЫЕ ПРЕПАРАТИВНЫЕ ФОРМЫ КЛАДРИБИНА
European Patent Office	1608343	PREPARATIONS A BASE DE CLADRIBINE PERMETTANT UNE ADMINISTRATION ORALE ET TRANSMUCOSALE AMELIOREE (CLADRIBINE FORMULATIONS FOR IMPROVED ORAL AND TRANSMUCOSAL DELIVERY)
Hungary	S1800013
China	101090726	Cladribine regimen for treating multiple sclerosis

Supplementary Protection Certificates for MAVENCLAD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1827461	C201830015	Spain		PRODUCT NAME: CLADRIBINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1212; DATE OF AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1212; DATE OF FIRST AUTHORISATION IN EEA: 20170822
1827461	CR 2018 00010	Denmark		PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824
1827461	122018000021	Germany		PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170822
1827461	C01827461/01	Switzerland		PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66831 19.03.2019
2805723	324 6-2018	Slovakia		PRODUCT NAME: KLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170824
1827461	9/2018	Austria		PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170824
1608344	PA2018502,C1608344	Lithuania		PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822

MAVENCLAD: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

MavenclAD (cladribine) is an oral nucleoside analog used for the treatment of relapsing forms of multiple sclerosis (MS). Its therapeutic mechanism involves selective depletion of lymphocytes.

What is the Current Patent Status for MavenclAD?

The patent landscape for MavenclAD is characterized by a primary composition of matter patent that has expired in key markets, alongside secondary patents covering methods of use and formulations.

• Composition of Matter Patent: The foundational patent for cladribine, US Patent 4,943,619, expired in November 2009. This patent covered the cladribine molecule itself. [1]
• Formulation and Method of Use Patents: Merck KGaA, the originator, has pursued secondary patents. For instance, US Patent 8,642,076, covering a specific oral formulation of cladribine, was granted in February 2014. This patent had an expected expiration date of December 17, 2023. [2] Other patents related to dosage regimens and treatment methods exist.
• Exclusivity in Key Markets: In the United States, MavenclAD received 5-year New Chemical Entity (NCE) exclusivity upon its approval in 2019 by the FDA. This exclusivity expired in March 2024. [3] In Europe, the European Medicines Agency (EMA) granted a 10-year data exclusivity period for MavenclAD, which would have concluded around March 2029. However, the expiry of the underlying patents significantly impacts market exclusivity.

What is the Market Opportunity for MavenclAD?

The market for MS therapeutics is substantial and growing, driven by increasing diagnosis rates and demand for effective disease-modifying therapies (DMTs).

• Global MS Market Size: The global multiple sclerosis market was valued at approximately $25 billion in 2022 and is projected to reach over $38 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 5.3% from 2023 to 2030. [4]
• Competitive Landscape: MavenclAD competes with a range of injectable and oral DMTs, including fingolimod, dimethyl fumarate, teriflunomide, and natalizumab. Newer therapies, such as siponimod and ocrelizumab, also represent significant competition.
• Geographic Penetration: MavenclAD is approved in over 70 countries, including the United States, European Union member states, Canada, and Australia. [5] Its adoption has been subject to payer formulary restrictions and physician prescribing patterns.
• Sales Performance: Merck KGaA reported net sales for MavenclAD of €654 million ($707 million) in 2023, an increase from €559 million ($605 million) in 2022, indicating continued market penetration. [6]

What are the Regulatory and Manufacturing Considerations?

Regulatory approvals and manufacturing processes are critical for market access and cost-effective production.

• FDA Approval: MavenclAD was approved by the U.S. Food and Drug Administration (FDA) in March 2019 for the treatment of relapsing forms of MS. [3]
• EMA Approval: The European Medicines Agency (EMA) approved MavenclAD in August 2017. [5]
• Manufacturing Process: Cladribine is a synthetic molecule. The manufacturing process involves chemical synthesis. The cost of goods sold (COGS) for generic cladribine products will be a key determinant of competitive pricing post-patent expiry.
• Potential for Generics: With the expiration of the primary composition of matter patent and the approaching expiry of formulation patents, the market is open to generic competition. Generic manufacturers will need to demonstrate bioequivalence to the branded product.

What is the Investment Outlook for MavenclAD-Related Opportunities?

The investment outlook for MavenclAD is bifurcated, with reduced opportunities for the originator and increased potential for generic manufacturers.

• Risk for Originator (Merck KGaA): Merck KGaA faces significant revenue erosion risk from generic competition following patent expiry, particularly in the United States and Europe. While its established market presence and brand recognition may offer some buffer, pricing pressure is anticipated to intensify.
• Opportunity for Generic Manufacturers: Companies developing generic versions of cladribine can capitalize on the established market demand and therapeutic profile of MavenclAD. The expiration of key patents presents a clear path to market entry.
• Biosimilar/Bioequivalent Development: The development of bioequivalent generic formulations requires significant R&D investment in formulation, analytical testing, and bioequivalence studies. Successful generic launches are contingent on navigating regulatory pathways efficiently and achieving cost-effective manufacturing.
• Market Dynamics Post-Patent Expiry: The introduction of generic cladribine will likely lead to a significant price reduction in the MS market, potentially increasing patient access and overall volume. However, originator market share is expected to decline.
• Valuation Considerations: For generic companies, valuation will hinge on the speed of market entry, manufacturing cost efficiency, and the competitive response from other generic players. For originator companies, the revenue decline from MavenclAD will need to be offset by pipeline growth.

Key Takeaways

MavenclAD's primary composition of matter patent has expired, opening the door for generic competition. While secondary patents related to formulation and method of use provided some market exclusivity, these are also nearing or have recently expired. The global multiple sclerosis market presents a substantial opportunity, but competition is intense. Merck KGaA, the originator, faces significant revenue risk from upcoming generic entrants. Conversely, generic manufacturers can leverage the established market for cladribine. Investment in generic cladribine development offers potential upside, provided efficient regulatory navigation and cost-effective manufacturing are achieved.

Frequently Asked Questions

1. When did the primary patent for cladribine expire?

The composition of matter patent for cladribine, US Patent 4,943,619, expired in November 2009.

2. What was the duration of New Chemical Entity (NCE) exclusivity for MavenclAD in the U.S.?

MavenclAD received 5-year NCE exclusivity upon its FDA approval in March 2019, which expired in March 2024.

3. Which company manufactures and markets MavenclAD?

Merck KGaA, Darmstadt, Germany, manufactures and markets MavenclAD.

4. What is the projected growth rate for the global multiple sclerosis market?

The global multiple sclerosis market is projected to grow at a CAGR of approximately 5.3% from 2023 to 2030.

5. What are the primary risks for Merck KGaA concerning MavenclAD's market exclusivity?

The primary risks are revenue erosion due to generic competition following the expiration of key patents and market exclusivity periods.

---

Citations

[1] United States Patent 4,943,619. (1990). Cladribine and process for its preparation. [Google Patents]

[2] United States Patent 8,642,076. (2014). Oral formulations of 2-chloro-2'-deoxyadenosine. [Google Patents]

[3] U.S. Food and Drug Administration. (2019, March 29). FDA approves Mavenclad (cladribine tablets) for the treatment of relapsing forms of multiple sclerosis. [Press release]

[4] Grand View Research. (2023). Multiple Sclerosis Market Size, Share & Trends Analysis Report By Disease Type (Relapsing-Remitting MS, Secondary Progressive MS, Primary Progressive MS, Progressive-Relapsing MS), By Drug Type (Chemotherapy, Immunomodulators, Others), By Region, And Segment Forecasts, 2023 – 2030.

[5] European Medicines Agency. (2017, August 23). MavenclAD approved in the EU for highly active relapsing multiple sclerosis. [Press release]

[6] Merck KGaA. (2024, February 29). Merck KGaA, Darmstadt, Germany, presents strong full-year 2023 results and announces outlook for 2024. [Press release]